- Conditions
- Depressive Disorder, Major
- Interventions
- Esketamine, Midazolam, Oral Placebo, Intranasal Placebo
- Drug · Other
- Lead sponsor
- Janssen Research & Development, LLC
- Industry
- Eligibility
- 12 Years to 17 Years
- Enrollment
- 258 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2026 – 2031
- U.S. locations
- 10
- States / cities
- Birmingham, Alabama • Washington D.C., District of Columbia • Atlanta, Georgia + 7 more
Location Directory
Clinical trials in Birmingham, Alabama
This page shows live ClinicalTrials.gov search results for Birmingham, Alabama, with direct links to official study records plus on-page filtering and sorting for broad location searches.
Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.
Official matching trials
9530
Shown on this page
12
Current sort
Recently updated
Location scope
Birmingham, AL
Filters apply within this location only.
These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.
Showing 769–780 of 9,530 matching trials in Birmingham, AL.
Live ClinicalTrials.gov results.
Institutions in Birmingham
Campus pages list official records that name the campus as a study site. Listed in directory order, not ranked.
Live official records
Open in full search- Conditions
- Eczema
- Interventions
- Abrocitinib, Placebo
- Drug · Other
- Lead sponsor
- Pfizer
- Industry
- Eligibility
- 6 Years to 11 Years
- Enrollment
- 150 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2025 – 2027
- U.S. locations
- 13
- States / cities
- Birmingham, Alabama • North Little Rock, Arkansas • San Diego, California + 7 more
- Conditions
- Acellular Dermal Matrix, Alveolar Mucosa
- Interventions
- Phase I dental implant placement with acellular dermis, Phase II dental implant uncovery with acellular dermis
- Procedure
- Lead sponsor
- University of Alabama at Birmingham
- Other
- Eligibility
- 18 Years to 85 Years
- Enrollment
- 40 participants
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- 2026 – 2028
- U.S. locations
- 1
- States / cities
- Birmingham, Alabama
- Conditions
- Asthma
- Interventions
- Benralizumab, Placebo
- Biological
- Lead sponsor
- AstraZeneca
- Industry
- Eligibility
- 18 Years to 70 Years
- Enrollment
- 75 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2019 – 2026
- U.S. locations
- 19
- States / cities
- Birmingham, Alabama • Los Angeles, California • Jacksonville, Florida + 16 more
- Conditions
- Non-Muscle Invasive Bladder Neoplasms
- Interventions
- Erdafitinib Intravesical Delivery System
- Drug
- Lead sponsor
- Janssen Research & Development, LLC
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 235 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2022 – 2029
- U.S. locations
- 25
- States / cities
- Birmingham, Alabama • Los Angeles, California • Lone Tree, Colorado + 22 more
- Conditions
- Atrial Fibrillation
- Interventions
- Milvexian, Apixaban, Placebo, Apixaban Placebo
- Drug
- Lead sponsor
- Janssen Research & Development, LLC
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 20,284 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2023 – 2026
- U.S. locations
- 216
- States / cities
- Alexander City, Alabama • Birmingham, Alabama • Dothan, Alabama + 182 more
- Conditions
- Juvenile Spondyloarthritis
- Interventions
- Standard TNFi Therapy, TNFi fixed longer dosing intervals, Stop TNFi treatment
- Other
- Lead sponsor
- Children's Hospital of Philadelphia
- Other
- Eligibility
- 8 Years to 21 Years
- Enrollment
- 164 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2021 – 2026
- U.S. locations
- 30
- States / cities
- Birmingham, Alabama • Phoenix, Arizona • Los Angeles, California + 27 more
- Conditions
- Leukemia, Myeloid, Acute
- Interventions
- Bleximenib, Venetoclax (VEN), Azacitidine (AZA), Cytarabine, Daunorubicin or Idarubicin
- Drug
- Lead sponsor
- Janssen Research & Development, LLC
- Industry
- Eligibility
- 12 Years and older
- Enrollment
- 196 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2022 – 2027
- U.S. locations
- 7
- States / cities
- Birmingham, Alabama • Duarte, California • Boston, Massachusetts + 4 more
- Conditions
- Catheter-Related Infections
- Interventions
- (taurolidine and heparin) catheter lock solution, Standard of Care
- Drug
- Lead sponsor
- CorMedix Therapeutics
- Industry
- Eligibility
- Up to 17 Years
- Enrollment
- 36 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2025 – 2029
- U.S. locations
- 6
- States / cities
- Birmingham, Alabama • Phoenix, Arizona • Palo Alto, California + 3 more
- Conditions
- Atrial Fibrillation
- Interventions
- VARIPULSE Catheter System, LAAO Device
- Device
- Lead sponsor
- Biosense Webster, Inc.
- Industry
- Eligibility
- 18 Years to 80 Years
- Enrollment
- 1,070 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2026 – 2031
- U.S. locations
- 11
- States / cities
- Birmingham, Alabama • Tucson, Arizona • Jonesboro, Arkansas + 8 more
- Conditions
- Liver Cirrhosis
- Interventions
- Part A: Placebo (matching zibotentan capsule & matching dapagliflozin tablet), Part A: zibotentan (dose B) + dapagliflozin, Part B: Placebo (matching zibotentan capsule & matching dapagliflozin tablet), Part B: placebo (matching zibotentan capsule) + dapagliflozin, Part B: zibotentan (dose A) + dapagliflozin, Part B: zibotentan (dose B) + dapagliflozin, Part B: zibotentan (dose C) + dapagliflozin
- Drug
- Lead sponsor
- AstraZeneca
- Industry
- Eligibility
- 18 Years to 80 Years
- Enrollment
- 205 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2022 – 2025
- U.S. locations
- 11
- States / cities
- Birmingham, Alabama • Pasadena, California • San Francisco, California + 8 more
- Conditions
- Carcinoma, Non-Small-Cell Lung
- Interventions
- Capmatinib, Amivantamab
- Drug
- Lead sponsor
- Janssen Research & Development, LLC
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 57 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2022 – 2027
- U.S. locations
- 5
- States / cities
- Birmingham, Alabama • Cerritos, California • Los Angeles, California + 2 more